{"id":"W4414849140","doi":"10.1038/s41591-025-03971-6","title":"Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Cilag; Regeneron Pharmaceuticals; National Institutes of Health; Gilead Sciences; LEO Pharma; University of Pennsylvania; Swedish Orphan Biovitrum; Medac; Galderma; XBiotech; Sun Pharma; Amgen; Rheumatology Research Foundation; Sanofi; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Versus Arthritis; Celgene; National Psoriasis Foundation; Pfizer; Biogen; Pacira BioSciences; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company","keywords":"Psoriatic arthritis; Clinical endpoint; Confidence interval; Odds ratio; Randomized controlled trial; Placebo; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00188737,0.001437402,0.001946989,0.0004712511,0.0003030277,0.0007322751,0.000554108,0.001727649,0.004949066],"category_scores_gemma":[0.001163319,0.0005512076,0.001306884,0.0003054613,0.0008484619,0.0008554432,0.0002917537,0.002172697,0.0008599574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004005929,"about_ca_system_score_gemma":0.0007533593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003576102,"about_ca_topic_score_gemma":0.0009077806,"domain_scores_codex":[0.9994678,0.0002876646,0.00002808919,0.00008979441,0.00005302526,0.00007364518],"domain_scores_gemma":[0.9994377,0.0001815674,0.0001320713,0.00002981271,0.00004112007,0.0001776254],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9463208,0.009269699,0.0006102635,0.001198457,0.0007618879,0.00007141029,0.00006783823,0.0003657859,0.006884015,0.0002609857,0.001351859,0.03283694],"study_design_scores_gemma":[0.9428289,0.05423561,0.0007258243,0.00003602379,0.0002734693,0.0000471657,0.00001345571,0.0003220625,0.0006306777,0.0001292995,0.0007472661,0.0000102745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9721185,0.01400985,0.001767191,0.001035325,0.0007794421,0.005637095,0.001545944,0.0002716185,0.00283503],"genre_scores_gemma":[0.9747939,0.006887308,0.002842639,0.002127131,0.0007046101,0.007020731,0.001386711,0.00004452591,0.004192424],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004949066,"threshold_uncertainty_score":0.01655626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009939838097560674,"score_gpt":0.3030443671438675,"score_spread":0.2931045290463068,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}